Novartis AG Stock (NVS) Opened Down by 12.63% on Sep 8: What Investors Need To Know

Novartis AG (NVS) opened down by 12.63%. The Pharmaceuticals & Medical Research sector is down by 2.02%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Johnson & Johnson (JNJ) down 1.94%; Eli Lilly and Co (LLY) down 1.81%; Pfizer Inc (PFE) down 1.23%.

What is driving Novartis AG (NVS)’s stock price down today?

The dramatic downward movement in Novartis AG shares is primarily driven by news that the company's high-stakes Phase III HARBOR trial for del-desiran failed to achieve its primary endpoint. The late-stage study, which evaluated the experimental therapy in patients with myotonic dystrophy type 1, showed no statistically significant improvement over placebo in video hand opening time. Del-desiran was a centerpiece asset acquired through the high-profile acquisition of Avidity Biosciences and was widely viewed by Wall Street as a critical late-stage growth driver with multi-billion-dollar peak sales potential. The failure to demonstrate clear efficacy severely undermines expectations for near-term commercialization in neuromuscular diseases.

This trial miss represents the latest in a rapid succession of pipeline disappointments, compounding negative sentiment across the institutional investor base. Just days prior, Novartis reported that its Phase III Lp(a)HORIZON trial for pelacarsen, an RNA-based cardiovascular candidate co-developed with Ionis Pharmaceuticals, failed to reduce major adverse cardiovascular events despite successfully lowering target protein levels. Furthermore, market participants remain cautious following the recent clinical suspension of multiple autoimmune studies evaluating its experimental cell therapy, rap-cel, due to safety concerns. Having missed on two major late-stage readouts within a single week, investor scrutiny has intensified regarding the execution of the broader research pipeline and the returns on recent strategic acquisitions.

From an equity research perspective, the sharp sell-off reflects a structural repricing of the company's growth risk premium as patent expirations on legacy blockbuster drugs approach over the coming years. Although management reiterated its mid-term revenue growth guidance and highlighted ongoing progress in alternative pipeline assets receiving priority regulatory reviews, the loss of two key late-stage candidates leaves a notable gap in projected late-decade cash flows. Until clarity emerges regarding potential secondary data pathways or replacement assets through disciplined capital deployment, market sentiment is likely to remain constrained by pipeline execution risk.

Technical Analysis of Novartis AG (NVS)

Technically, Novartis AG (NVS) shows a MACD (12,26,9) value of -1.639, indicating a neutral signal. The RSI at 33.438 suggests neutral condition and the Williams %R at 96.470 suggests oversold condition. Please monitor closely.

Fundamental Analysis of Novartis AG (NVS)

Novartis AG (NVS) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $56.33B, ranking 9 in the industry. The net profit is $13.98B, ranking 5 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Hold, with an average price target of $146.56, a high of $185.00, and a low of $106.21.

More details about Novartis AG (NVS)

Company Specific Risks:

• Phase III HARBOR Trial Failure for Del-Desiran: On September 8, 2026, Novartis announced that del-desiran, the lead asset from its $12 billion Avidity Biosciences acquisition, failed to meet its primary endpoint of video hand opening time in the Phase III HARBOR trial for myotonic dystrophy type 1. The setback sent NVS shares down over 9% intraday and prompted analysts at Vontobel and UBS to strip up to $3 billion in projected peak annual sales from their valuation models.
• Pelacarsen Cardiovascular Trial Endpoint Miss: On September 7–8, 2026, Novartis reported that pelacarsen, licensed from Ionis Pharmaceuticals, failed to meet its primary endpoint in the Phase III Lp(a)HORIZON cardiovascular outcomes study. Although pelacarsen successfully lowered lipoprotein(a) levels, it failed to demonstrate a statistically significant reduction in major adverse cardiovascular events, damaging a core asset expected to drive long-term revenue.
• Clinical Trial Freeze Following Patient Fatalities: Novartis paused eight clinical trials across its experimental CAR-T cell therapy pipeline (rap-cel) for autoimmune diseases following the deaths of three trial participants. The safety hold halts development of the company's next-generation cell therapy portfolio and increases regulatory exposure.
• Analyst Skepticism Over 2030 Revenue Growth Targets: Following three major clinical failures within a single week, institutional analysts at Barclays and Jefferies publicly questioned Novartis's ability to achieve its stated 5% to 6% annual sales growth target through 2030. Analysts highlighted that accelerating generic competition on established blockbusters like Entresto, coupled with pipeline failures, leaves the company's growth strategy heavily reliant on uncertain future M&A.